Soluble TREM2 regulation of microglial function in Alzheimer disease
Soluble TREM2 regulation of microglial function in Alzheimer disease
批准号:
10432584
负责人:
MARCO COLONNA
金额:
$43.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-05-05 至 2024-04-30
关键词:
AffectAgeAlzheimer&aposs DiseaseAmericanAmyloid beta-ProteinApoptoticBindingBinding ProteinsBrainCRISPR/Cas technologyCandidate Disease GeneCause of DeathCellsChimeric ProteinsDementiaDepositionDevelopmentDiseaseEngineeringFunctional disorderGeneticHumanImmunologic ReceptorsIntegral Membrane ProteinIntrathecal InjectionsKnockout MiceLipoproteinsMembraneMicrogliaModelingMusPathologyPhagocytosisPhospholipidsPreventionProteinsRegulationRiskRisk FactorsSenile PlaquesSignal TransductionSliceTREM2 geneTYROBP geneTimeUnited StatesVariantbeta amyloid pathologybrain cellcognitive functioncost estimateefficacy evaluationexperimental studygenetic variantgenome wide association studyimprovedmouse modelnovel strategiesnovel therapeuticsprotein aggregationreceptorreceptor bindingtherapy developmenttoolwhole genome
中文摘要
项目摘要
阿尔茨海默病(AD)是美国第六大死亡原因,
美国人患有这种疾病。今年,AD和其他痴呆症的估计成本为3050亿美元,
到2050年将达到1.1万亿美元。AD的病因仍然难以捉摸,可能是多因素的。最大的风险
已知的因素是年龄、遗传和遗传。全基因组关联研究表明,
TREM 2的变体与发展成AD的风险的2至4倍相关。TREM 2是一种先天免疫
在小胶质细胞中表达的受体,已显示与磷脂、凋亡细胞、脂蛋白
和淀粉样蛋白-β(Aβ)的寡聚体形式。这种蛋白质已被证明是小胶质细胞增殖所必需的,
存活和吞噬Aβ。TREM 2是不具有胞内信号传导结构域的跨膜蛋白;
信号转导需要与DAP 12结合。在小胶质细胞活化和成簇后,TREM 2被切割,
所述膜产生可溶性TREM 2(sTREM 2)。由于膜结合的TREM 2和sTREM 2都是
在AD的不同阶段共存,很难区分每种形式的程度
独立地对疾病病理学有贡献。最近显示鞘内给药后,
sTREM 2与小胶质细胞结合,传递细胞内信号,促进存活,改善认知功能,
并减轻Aβ病理学;据推测sTREM 2通过一种推定的但未知的受体起作用。
在这项提案中,我们将利用CRISPR/Cas9全基因组筛选来鉴定结合sTREM 2的受体
并促进信号转导。确定的候选基因将在人类小胶质细胞中进行验证。
细胞和基因敲除小鼠模型将被生成,以进一步探索每一个在发展中的重要性。
AD及其病理生理学。这些模型将作为工具,使我们能够确定sTREM 2
独立于膜结合的TREM 2调节小胶质细胞。这一发现将成为
旨在调节sTREM 2受体的新疗法。sTREM 2也被证明与Aβ结合
斑块我们将利用这一观察结果并开发sTREM 2-可结晶级分(sTREM 2-Fc)融合蛋白。
结合Aβ斑块并促进小胶质细胞活化和吞噬作用的蛋白质类。sTREM 2-Fc融合体
将使用来自5XFAD小鼠的脑切片来验证蛋白质,所述小鼠积累AD的典型A β斑块。我们
还将进行鞘内注射,这将使我们能够评估sTREM 2-Fc在消除
斑块和活化的小胶质细胞。总之,这些都是新的方法,可能有助于开发治疗方法
其增强清除和预防淀粉样蛋白-β斑块形成以治疗AD。
英文摘要
PROJECT SUMMARY
Alzheimer's Disease (AD) is the 6th leading cause of death in the United States and more than 5.8 million
Americans suffer from this disease. This year the estimated cost of AD and other dementias is $305 billion, and
could rise to $1.1 trillion by 2050. The cause of AD remains elusive and is likely multifactorial. The greatest risk
factors are known to be age, genetics, and inheritance. Genome-wide association studies have shown that
variants of TREM2 are associated with two to four times the risk of developing AD. TREM2 is an innate immune
receptor expressed in microglia that has been shown to interact with phospholipids, apoptotic cells, lipoproteins,
and oligomeric forms of amyloid-β (Aβ). This protein has been shown to be required for microglial proliferation,
survival, and phagocytosis of Aβ. TREM2 is a transmembrane protein with no intracellular signaling domains;
signal transduction requires binding to DAP12. Upon microglial activation and clustering, TREM2 is cleaved from
the membrane generating soluble TREM2 (sTREM2). Since both membrane-bound TREM2 and sTREM2
coexist during different stages of AD, it has been difficult to differentiate the extent of which each form
independently contributes to disease pathology. It was recently shown that after intrathecal administration,
sTREM2 binds to microglia, transmitting intracellular signals, promoting survival, improving cognitive function,
and mitigating Aβ pathology; it has been postulated that sTREM2 acts through a putative yet unknown receptor.
In this proposal we will utilize a CRISPR/Cas9 whole genome screen to identify the receptor that binds sTREM2
on microglia and promotes signal transduction. Identified candidate genes will be validated in human microglial
cells and knockout mouse models will be generated to further explore the importance of each in the development
of AD and its pathophysiology. These models will serve as tools that will permit us to identify how sTREM2
modulates microglia independently from membrane-bound TREM2. Such discovery will serve as the basis for
novel therapeutics aimed at modulation of the sTREM2 receptor. sTREM2 has also been shown to bind Aβ
plaques. We will exploit this observation and develop sTREM2-fraction crystallizable(sTREM2-Fc) fusion
proteins that bind Aβ plaques and promote activation of microglia and phagocytosis. The sTREM2-Fc fusion
proteins will be validated using slices of brains from 5XFAD mice that accumulate A plaques typical of AD. We
will also perform intrathecal injections, which will allow us to evaluate the efficacy of sTREM2-Fc in eliminating
plaques and activating microglia. Taken together, these are novel approaches that may help to develop therapies
that enhance clearance and prevention of amyloid-β plaque formation for the treatment of AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mucosal Immune Defense Mechanisms of the Urinary Bladder
-
批准号:10587639
-
项目类别:
-
资助金额:$62.28万
-
财政年份:2023
-
负责人:MARCO COLONNA
-
依托单位:
Impact of polyamines on ILC3 function at steady state and in preclinical model of colitis
-
批准号:10528082
-
项目类别:
-
资助金额:$19.69万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
The protein tyrosine kinase SYK drives innate immune responses against Alzheimer's Disease
-
批准号:10674689
-
项目类别:
-
资助金额:$59.72万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
Impact of polyamines on ILC3 function at steady state and in preclinical model of colitis
-
批准号:10623342
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
Ontogenetic niche of B cells at the CNS borders in homeostasis, aging and autoimmunity
-
批准号:10446266
-
项目类别:
-
资助金额:$62.45万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
Ontogenetic niche of B cells at the CNS borders in homeostasis, aging and autoimmunity
-
批准号:10557870
-
项目类别:
-
资助金额:$59.89万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEIN
-
批准号:10321553
-
项目类别:
-
资助金额:$41.51万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
Targeting TREM2 to boost anti-cancer therapy
-
批准号:10477296
-
项目类别:
-
资助金额:$43.23万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
Targeting TREM2 to boost anti-cancer therapy
-
批准号:10279674
-
项目类别:
-
资助金额:$41.62万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEIN
-
批准号:10539270
-
项目类别:
-
资助金额:$41.03万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
Targeting TREM2 to boost anti-cancer therapy
-
批准号:10689150
-
项目类别:
-
资助金额:$43.23万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
Plasticity of Innate Lymphoid Cells: Mechanisms and Biological Impact
-
批准号:10597244
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2020
-
负责人:MARCO COLONNA
-
依托单位:
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis
-
批准号:10265677
-
项目类别:
-
资助金额:$24.13万
-
财政年份:2020
-
负责人:MARCO COLONNA
-
依托单位:
Plasticity of Innate Lymphoid Cells: Mechanisms and Biological Impact
-
批准号:10363734
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2020
-
负责人:MARCO COLONNA
-
依托单位:
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis
-
批准号:10219643
-
项目类别:
-
资助金额:$35.86万
-
财政年份:2020
-
负责人:MARCO COLONNA
-
依托单位:
Impact of Airway Epithelium on Innate and Adaptive Immunity in the Lung
-
批准号:10371236
-
项目类别:
-
资助金额:$33.39万
-
财政年份:2019
-
负责人:MARCO COLONNA
-
依托单位:
Impact of Airway Epithelium on Innate and Adaptive Immunity in the Lung
-
批准号:10579869
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2019
-
负责人:MARCO COLONNA
-
依托单位:
Impact of Airway Epithelium on Innate and Adaptive Immunity in the Lung
-
批准号:10113529
-
项目类别:
-
资助金额:$37.16万
-
财政年份:2019
-
负责人:MARCO COLONNA
-
依托单位:
CIS-REGULATORY CIRCUITS FOR ILC FUNCTION AND PLASTICITY
-
批准号:10219921
-
项目类别:
-
资助金额:$65.0万
-
财政年份:2018
-
负责人:MARCO COLONNA
-
依托单位:
CIS-REGULATORY CIRCUITS FOR ILC FUNCTION AND PLASTICITY
-
批准号:9762835
-
项目类别:
-
资助金额:$68.6万
-
财政年份:2018
-
负责人:MARCO COLONNA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: